{"id":549,"date":"2026-06-15T11:34:25","date_gmt":"2026-06-15T15:34:25","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=549"},"modified":"2026-06-15T11:34:27","modified_gmt":"2026-06-15T15:34:27","slug":"u-s-supreme-court-reverses-federal-circuit-holding-no-induced-infringement-plausibly-pled-based-on-skinny-label-and-related-statements","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2026\/06\/15\/u-s-supreme-court-reverses-federal-circuit-holding-no-induced-infringement-plausibly-pled-based-on-skinny-label-and-related-statements\/","title":{"rendered":"U.S. Supreme Court Reverses Federal Circuit, Holding No Induced Infringement Plausibly Pled Based on Skinny Label and Related Statements"},"content":{"rendered":"\n<p>By \u00a0<a href=\"https:\/\/www.duanemorris.com\/attorneys\/jasonluo.html\">Jiazhong (Jason) Luo, Ph.D.<\/a> and\u00a0<a href=\"https:\/\/www.duanemorris.com\/attorneys\/frederickrball.html\">Frederick R. Ball<\/a><\/p>\n\n\n\n<p>Recently, the Supreme Court of the United States unanimously reversed the Federal Circuit in <em>Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.<\/em>, holding that Amarin failed to state a claim for active inducement of patent infringement under 35 U.S.C. \u00a7 271(b). The decision clarifies that the relevant inquiry is whether a defendant actively encouraged infringing use, not merely whether physicians could plausibly read the defendant\u2019s statements related to a skinny label as instructions to infringe.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.duanemorris.com\/alerts\/us_supreme_court_reverses_federal_circuit_court_holding_no_skinny_label_infringement_0626.html\">Read the full <em>Alert<\/em> on the Duane Morris LLP website<\/a>.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>By \u00a0Jiazhong (Jason) Luo, Ph.D. and\u00a0Frederick R. Ball Recently, the Supreme Court of the United States unanimously reversed the Federal Circuit in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., holding that Amarin failed to state a claim for active inducement of patent infringement under 35 U.S.C. \u00a7 271(b). The decision clarifies that the relevant &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2026\/06\/15\/u-s-supreme-court-reverses-federal-circuit-holding-no-induced-infringement-plausibly-pled-based-on-skinny-label-and-related-statements\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;U.S. Supreme Court Reverses Federal Circuit, Holding No Induced Infringement Plausibly Pled Based on Skinny Label and Related Statements&#8221;<\/span><\/a><\/p>\n","protected":false},"author":109,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[209,693,221,495,560,567,733],"ppma_author":[533,527],"class_list":["post-549","post","type-post","status-publish","format-standard","hentry","category-general","tag-frederick-ball","tag-jason-luo","tag-life-sciences","tag-life-sciences-and-medical-technologies","tag-patent-infringement","tag-skinny-label","tag-u-s-supreme-court"],"authors":[{"term_id":533,"user_id":109,"is_guest":0,"slug":"jluo","display_name":"Jason Luo, Ph.D.","avatar_url":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-content\/uploads\/sites\/15\/2014\/08\/luojiazhong-125x150.jpg","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""},{"term_id":527,"user_id":33,"is_guest":0,"slug":"frball","display_name":"Frederick R. Ball","avatar_url":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-content\/uploads\/sites\/15\/2018\/10\/ballfrederick-125x150.jpg","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/549","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/109"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=549"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/549\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=549"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=549"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=549"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=549"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}